Saturday 17 October 2026
Export NSRX’s income statement to Excel — free account
Nasus Pharma Ltd.
NSRX Healthcare Drug Manufacturers General
Insiders bought in the last twelve months.
3.18
0.01
+0.32%
Follow NSRX
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+1 more TTM period Free account |
— | — | — | 0.00% | |
| — | — | — | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow |
— | — | (7.04) | (12.07) | |
Capital Expenditures |
— | — | — | (0.02) | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | (173.56%) | (63.86%) | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | — | 0.00 | 0.00 | |
Depreciation/Fixed assets |
— | — | — | 0.00 | |
Capex/Depreciation |
— | — | — | 0.00 | |
Operating CF per Share |
— | — | 0.00 | 0.00 | |
Capex per Share |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates